Where are we, and where are we going?
melanoma
NON-SMALL CELL LUNG CANCER, MELANOMA, SOLID TUMORS, CERVICAL CANCER, GASTRIC CANCER
Immune-based regimens have been the standard recommendation in the treatment guidelines for more and more solid tumors, such as non-small cell lung cancer, melanoma, and gastric cancer. And for advanced cervical cancer, we have also made significant progress, and the immune-based treatment era is also closer and closer. However, we still lack the support of a large number of multicentered, randomized, controlled phase III clinical trials.From The clinical trials for recurrent/metastatic cervical cancer with published results.ITT, intend to treat; HR, hazard ratio.Nonetheless, the published results of some clinical trials are also worthy of our excitement and expectation. Most immune-based regimens represent higher ORRs than the standard treatments or immunotherapy alone, both in the first line and the second line or above. And the ORRs in PD-L1 positive subgroup is usually higher than in PD-L1 negative subgroup (